AVRICORE HEALTH CORPORATE UPDATE: Q1 Results and Ongoing Progress Report

Core Insights - Avricore Health Inc. reported first-quarter 2025 revenues of $434,061 and a gross profit of $346,297, with a comprehensive loss of $77,300 and a net cash increase of $137,068 [1][3] Financial Performance - For the fiscal year 2024, total revenue was $4,785,711, an increase from $3,485,147 in 2023 and $1,768,374 in 2022 [8] - The company experienced a loss from operations of $668,977 in 2024, slightly improved from $701,215 in 2023 and $818,228 in 2022 [8] - Total assets decreased to $2,298,544 in 2024 from $2,538,205 in 2023 and $2,568,983 in 2022 [8] Business Strategy - The company is expanding its HealthTab platform in the UK, aligning with the region's healthcare market and investment in pharmacy-led services [2] - Despite a scale-down of revenues in Canada, the company maintains a strong cash position and is well-positioned to meet its expansion objectives [3] Market Context - Global healthcare systems face increasing pressure due to budget constraints and clinician shortages, with over 6 million Canadians lacking access to a family doctor [4] - Pharmacy services are becoming crucial in delivering primary care, with HealthTab providing pharmacists with tools for essential screenings and patient engagement [5][6] HealthTab Overview - HealthTab is a point-of-care testing solution that offers rapid, lab-accurate results for chronic disease management, including diabetes and heart disease [13] - The platform empowers pharmacists in primary care delivery, reduces costs and waiting times, and creates multiple revenue streams [14]